16 September 2024
Please find attached Capital Change Notice relating to the issue of unlisted Performance Share Rights to employees
Ross O'Neill
Company Secretary
The pharmaceutical firm is pushing for approval of multiple phase-three trials in 2026.
Foot traffic is up, but margins are down.
Electricity generators are anxious to avoid winter power price spikes.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details